Business
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin
About this update from Cosmos Health Inc.
[{"type":"text","content":"Revenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segmentsGross profit growing 801% to $71.2M: Margins expanding from 12.1% to 35.5% — driven by a structural shift toward high-margin proprietary segmentsNet income improving by $50.1M: Transition to profitability in 2027; net income of $31.0 million by 2029Self-funding growth model: Operating cash flow turning positive in 2027 at $11.9 million, more than doubling to $24.0 million by 2029Balance sheet transformation: Cash up 18-fold to $62.9 million; all convertible notes repaid; cash anticipated to exceed total debt levels by 2027Shareholder value: stockholders' equity up 402% to $92.3 million and per-share value creation with EPS of $0.73 by 2029Clear growth drivers: High-margin proprietary products, expansion of the distribution and manufacturing platform, global partnerships, advancement of the R&D pipeline, AI-driven efficiencies, and disciplined capital allocation — with the U.S. serving as a new growth engine alongside selective M&A activity CHICAGO, May 26, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (\"Cosmos Health\" or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its financial guidance for the 2026–2029 period. Cosmos Health enters this guidance period following its strongest financial performance in Company history — full year 2025 revenue of $65.3 million, up 20% year-over-year, with gross profit increasing 83%, gross margin expanding 418 basis points, and cash rising more than tenfold to $3.5 million. This momentum has carried into 2026 across all core segments, with the Company expecting to surpass $90 million in revenue in 2026, representing approximately 38% year-over-year growth, and continued strong growth anticipated through 2029. By 2029, Cosmos Health projects revenue of $200.6 million, gross profit of $71.2 million, net income of $31.0 million, Adjusted EBITDA of $44.2 million, and cash of $62.9 million, with all convertible debt expected to be fully repaid and stockholders’ equity projected to increase 402% to $92.3 million. Management believes this financial trajectory could create a powerful compounding effect across the Company's operations, balance sheet, and profitability profile — supporting its long-...